Loading
In this Chinese randomised trial, chemotherapy with temozolomide and cisplatin after surgery for mucosal melanoma lengthened relapse-free and overall survival compared with interferon or observation, the only positive adjuvant trial specific to mucosal disease.
Phase 2 randomised trial of 189 patients with resected mucosal melanoma assigned to observation, high-dose interferon alfa-2b for one year, or six cycles of temozolomide plus cisplatin.
Median relapse-free survival was 5.4 months with observation, 9.4 months with interferon and 20.8 months with chemotherapy, and median overall survival 21.2, 40.4 and 48.7 months respectively.
Adjuvant temozolomide-cisplatin is used in China for resected mucosal melanoma; elsewhere anti-PD-1 therapy is extrapolated from cutaneous disease, and the two have since been compared directly.
Shares Temozolomide, Cisplatin.
Shares Temozolomide, Cisplatin.
Shares Clinical Cancer Research, Cisplatin.
Shares Temozolomide, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/